Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5981334 | 1.00 | TRHR (0.52) | TRHR | |
| SCHEMBL7327696 | 1.00 | TRHR (0.52) | TRHR | |
| SCHEMBL7327689 | 1.00 | TRHR (0.52) | TRHR | |
| SCHEMBL7371951 | 1.00 | TRHR (0.52) | TRHR | |
| Water SCHEMBL3090262 | 0.99 | TRHR (0.51) | TRHR | |
| SCHEMBL7324766 | 0.88 | TRHR (0.53) | TRHR | |
| SCHEMBL7326652 | 0.86 | TRHR (0.56) | TRHR | |
| SCHEMBL7334062 | 0.86 | TRHR (0.56) | TRHR | |
| SCHEMBL7323141 | 0.86 | TRHR (0.49) | TRHR | |
| SCHEMBL7377796 | 0.85 | TRHR (0.37) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076288-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2066355-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | Braincells, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008036678-A2 | COMBINATION COMPRISING A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGENT AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER, INCREASING NEURODIFFERENTIATION AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036846-A2 | COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITOR AND A SECOND NEUROGENIC AGENT FOR TREATING A NERVOUS SYSTEM DISORDER AND INCREASING NEUROGENESIS | BRAINCELLS, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
| US-7129256-B2 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20030191120-A1 | Antiparkinsonism drugs | SHIONOGI & CO., LTD. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1321151-A1 | ANTIPARKINSONISM DRUGS | SHIONOGI & CO., LTD. (JP) | 2003-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103105-A1 | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS | HMGCR, DCX, SREBF1 | TRHR 2371/4885 |
| US-20080103165-A1 | PPAR MEDIATED MODULATION OF NEUROGENESIS | PPARG, PPARA, PPARD | TRHR 675/4885 |
| US-20030191120-A1 | Antiparkinsonism drugs | PARK7, SNCA, NLN | TRHR 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.